IRLAB Therapeutics (IRLAB) Q2 2024 earnings summary

Executive summary

• Initiated Phase I clinical study for IRL757, targeting apathy in Parkinson's and Alzheimer's, fully funded by The Michael J. Fox Foundation and MSRD/Otsuka collaboration.

• REACT-PD Phase IIb study with pirepemat passed final DSMB review, progressing towards completion.

• Kristina Torfgård appointed as new CEO, effective August 1, 2024.

• Achieved significant milestones in clinical development, including advancing mesdopetam and pirepemat programs.

• Received strong external validation and financial support from The Michael J. Fox Foundation.

Financial highlights

• Net sales for H1 2024 reached SEK 42.8 million, up from SEK 6.9 million in H1 2023.

• Operating loss narrowed to SEK -42.7 million from SEK -104.4 million year-over-year.

• Cash position at quarter-end was SEK 98.3 million, down from SEK 156.4 million a year earlier.

• Cash flow from operating activities improved to SEK -38.1 million from SEK -94.3 million year-over-year.

• Earnings per share (EPS) before and after dilution improved to SEK -0.89 from SEK -2.01 year-over-year.

Outlook and guidance

• Mesdopetam Phase III study planned to start by end of 2024 or early 2025, with regulatory and market strategy development ongoing.

• Pirepemat Phase IIb patient recruitment expected to complete in Q3 2024, with top-line data anticipated by end of Q1 2025.

• IRL942 and IRL1117 projected to be Phase I ready in H2 2024/H1 2025.

• Ongoing efforts to secure additional partnerships and financing for future development.

• IRL757 fully funded through Proof-of-Concept, with further development in partnership with MSRD/Otsuka.